Search by Drug Name or NDC

NDC 14537-0834-03 Additive Formula 3 .03; .042; 1.1; .41; .28; .59 g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL Details

Additive Formula 3 .03; .042; 1.1; .41; .28; .59 g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL

Additive Formula 3 is a INTRAVENOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Terumo BCT, Ltd. The primary component is ADENINE; CITRIC ACID MONOHYDRATE; DEXTROSE MONOHYDRATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; TRISODIUM CITRATE DIHYDRATE.

Product Information

NDC	14537-0834
Product ID	14537-834_a7c8359b-69ef-497d-85f9-205ffdec83cb
Associated GPIs
GCN Sequence Number	n/a
GCN Sequence Number Description	n/a
HIC3	n/a
HIC3 Description	n/a
GCN	n/a
HICL Sequence Number	n/a
HICL Sequence Number Description	n/a
Brand/Generic	n/a
Proprietary Name	Additive Formula 3
Proprietary Name Suffix	n/a
Non-Proprietary Name	Dextrose Monohydrate, TRISODIUM CITRATE DIHYDRATE, Sodium Chloride, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, Citric Acid Monohydrate, and Adenine
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	SOLUTION
Route	INTRAVENOUS
Active Ingredient Strength	.03; .042; 1.1; .41; .28; .59
Active Ingredient Units	g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL
Substance Name	ADENINE; CITRIC ACID MONOHYDRATE; DEXTROSE MONOHYDRATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; TRISODIUM CITRATE DIHYDRATE
Labeler Name	Terumo BCT, Ltd
Pharmaceutical Class	Acidifying Activity [MoA], Acidifying Activity [MoA], Anti-coagulant [EPC], Anti-coagulant [EPC], Calcium Chelating Activity [MoA], Calcium Chelating Activity [MoA], Calculi Dissolution Agent [EPC], Calculi Dissolution Agent [EPC], Decreased Coagulation F
DEA Schedule	n/a
Marketing Category	NDA
Application Number	BN001214
Listing Certified Through	2024-12-31

Package

Package Images

NDC 14537-0834-03 (14537083403)

Pricing Information	N/A
NDC Package Code	14537-834-03
Billing NDC	14537083403
Package	24 BAG in 1 CASE (14537-834-03) / 350 mL in 1 BAG (14537-834-00)
Marketing Start Date	2002-05-29
NDC Exclude Flag	N

Standard Product Labeling (SPL)/Prescribing Information SPL 9a5247a1-cc05-442d-b2d0-950f887f03c2 Details

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ADDITIVE SOLUTION FORMULA 3 (AS-3) safely and effectively. See full prescribing information for ADDITIVE SOLUTION FORMULA 3 (AS-3).

ADDITIVE SOLUTION FORMULA 3 (AS-3)

Sterile Fluid

Polyolefin Bag

Initial U.S. Approval: 2002

INDICATIONS AND USAGE

Use only with Trima Accel red blood cell (RBC) apheresis collections. (1)

DOSAGE AND ADMINISTRATION

AS-3 is added to tubing sets after apheresis collections, after the donor has been disconnected. (2)
AS-3 may only be used with the Trima Accel apheresis device. For instructions on the use of the solution see the device operator's manual. (2.1)
Follow the directions for connecting the AS-3 bag to the tubing set of a blood collection system. (2.2)

DOSAGE FORMS AND STRENGTHS

100 mL, 200 mL, or 350 mL sterile fluid in a Polyolefin bag. (3)

CONTRAINDICATIONS

DO NOT INFUSE AS-3 DIRECTLY TO THE DONOR. (4)

WARNINGS AND PRECAUTIONS

Verify that the AS-3 bag has been securely attached to the system tubing set. Use aseptic technique throughout all procedures to ensure product quality. (5)
Do not reuse. Discard unused or partially used solution bags.

ADVERSE REACTIONS

Citrate reactions or toxicity may occur with the infusion of blood containing citrate. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Terumo BCT, Inc. at 1-877-339-4228 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Revised: 12/2021

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information

2.2 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

6 ADVERSE REACTIONS

8 USE IN SPECIFIC POPULATIONS

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

*: Sections or subsections omitted from the full prescribing information are not listed.

1 INDICATIONS AND USAGE

Use only with Trima Accel red blood cell (RBC) apheresis collections. [See Dosage and Administration (2).]

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information

ADDITIVE SOLUTION FORMULA 3 (AS-3) is connected to the tubing set used for an apheresis RBC collection procedure after the collection has been completed.

For automated RBC procedures, the recommended dose is determined by the apheresis device and metered into the tubing set by the apheresis device.
To add the product manually, refer to the apheresis system operator's manual to determine the recommended dose.

For instructions on the use of the solution with the apheresis device and tubing set, see the device operator's manual.

2.2 Administration

Directions for connecting the ADDITIVE SOLUTION FORMULA 3 (AS-3) bag to the apheresis device.

Automated RBC additive solution procedures:

Connect ADDITIVE SOLUTION FORMULA 3 (AS-3) after the collection is over and the donor is disconnected. For automated addition of the product, the system will prompt you to connect the bag.

Remove the overwrap by pulling down at notch, and remove the AS-3 bag.
Before use, perform the following checks:
- Ensure that the solution is the ADDITIVE SOLUTION FORMULA 3 (AS-3) and is within the expiration date.
- Inspect the bag in good light. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration. Check for leaks by gently squeezing the bag. If leaks are found, discard the bag.
- Inspect the solution in good light. Use only if solution is clear and free of particulate matter. Bags showing cloudiness, haze, or particulate matter should not be used.
- Protect from sharp objects.
Remove the protective cap from the port on the bag.
Connect the bag to the complementary luer of the apheresis device tubing set using aseptic technique and hang the solution.
Break the frangible connector. When you break frangible connectors, bend them in both directions to ensure that you break them completely. Failure to do so may result in restricted flow.
Proceed according to the apheresis device operator's manual.

Manual RBC additive solution procedures:

Connect ADDITIVE SOLUTION FORMULA 3 (AS-3) after the collection is over and the donor is disconnected.

Seal the RBC product lines as close to the cassette as possible.
Remove the overwrap by pulling down at notch, and remove the ADDITIVE SOLUTION FORMULA 3 bag.
Before use, perform the following checks:
- Ensure that the solution is the ADDITIVE SOLUTION FORMULA 3 (AS-3) and is within the expiration date.
- Inspect the bag in good light. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration. Check for leaks by gently squeezing the bag. If leaks are found, discard the bag.
- Inspect the solution in good light. Use only if solution is clear and free of particulate matter. Bags showing cloudiness, haze, or particulate matter should not be used.
- Protect from sharp objects.
Remove the protective cap from the port on the bag.
Insert the spike of the apheresis device tubing set into the spike port of the solution bag using aseptic technique and then hang the solution.
Proceed according to the apheresis device operator's manual.

3 DOSAGE FORMS AND STRENGTHS

100 mL, 200 mL and 350 mL ADDITIVE SOLUTION FORMULA 3 (AS-3) products are sterile solutions in a Polyolefin bag. Each 100 mL contains: Dextrose Monohydrate USP 1.10 g; Trisodium Citrate Dihydrate USP 0.59 g; Sodium Chloride USP 0.41 g; Monobasic Sodium Phosphate Monohydrate USP 0.28 g; Citric Acid Monohydrate USP 0.042 g; Adenine USP 0.03 g; and Water for Injection USP.

4 CONTRAINDICATIONS

DO NOT INFUSE ADDITIVE SOLUTION FORMULA 3 (AS-3) DIRECTLY TO THE DONOR.

5 WARNINGS AND PRECAUTIONS

Verify that the AS-3 bag has been securely attached to the system tubing set. Use aseptic technique throughout all procedures to ensure product quality.
Do not reuse. Discard unused or partially used solution bags.

6 ADVERSE REACTIONS

Citrate reactions or toxicity may occur with the infusion of blood products to patients. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by hypotension and possible cardiac arrhythmia. Citrate toxicity may occur more frequently in patients who are hypothermic, have impaired liver or renal function, or have low calcium levels because of an underlying disease.

8 USE IN SPECIFIC POPULATIONS

ADDITIVE SOLUTION FORMULA 3 (AS-3) has not been studied in controlled clinical trials with specific populations.

11 DESCRIPTION

ADDITIVE SOLUTION FORMULA 3 (AS-3) is designed to be added to packed RBC collected in apheresis procedures, and acts to preserve and extend the shelf life of packed RBC products for later transfusion to patients. The solution is intended to be metered by an apheresis device during apheresis procedures or added manually after a collection.

Additive Solution Formula 3 (AS-3) is a clear solution that is steam-sterilized and non-pyrogenic. It does not contain bacteriostatic or antimicrobial agents.

The formulas of the active ingredients are provided in Table 1.

Table 1: Active Ingredients
Ingredients	Molecular Formula	Molecular Weight
Dextrose Monohydrate USP	C6H12O6 ∙ H2O	198.17
Trisodium Citrate Dihydrate USP	C6H9Na3O9	294.10
Sodium Chloride USP	NaCl	58.44
Monobasic Sodium Phosphate Monohydrate USP	NaH2PO4 ∙ H2O	137.99
Citric Acid Monohydrate USP	C6H807 ∙ H2O	210.14
Adenine USP	C5H5N5	135.13
Water for Injection USP	H2O	18.00

Each 100 mL of ADDITIVE SOLUTION FORMULA 3 (AS-3) contains: Dextrose Monohydrate USP 1.10 g; Trisodium Citrate Dihydrate USP 0.59 g; Sodium Chloride USP 0.41 g; Monobasic Sodium Phosphate Monohydrate USP 0.28 g; Citric Acid Monohydrate USP 0.042 g; Adenine USP 0.03 g; and Water for Injection USP.

ADDITIVE SOLUTION FORMULA 3 is available in three volumes: 100 mL, 200 mL and 350 mL.

The 100 mL bags are individually wrapped with a clear plastic film. Six individually wrapped bags are then vacuum-sealed in a foil pouch, which serves as a vapor barrier to prevent water loss during storage. After you remove the individual solution bags from the foil pouch, you can either leave them in the clear plastic film or remove and discard it. Once the foil pouch has been opened, use all six of the solution bags within 2 weeks.

The 200 mL and 350 mL bags are individually wrapped with a clear plastic film. These larger volumes do not require the additional vapor barrier. Once the clear plastic film has been removed, use the solution within 2 weeks.

The Polyolefin bag is not made with natural rubber latex.

The bag is made from a multilayered film. It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions. The bag is nontoxic and biologically inert. The bag-solution unit is a closed system and is not dependent upon entry of external air during administration.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

ADDITIVE SOLUTION FORMULA 3 acts to preserve and extend the shelf life of packed RBC products for later transfusion to patients. The following ingredients are key components of the solution:

Adenine to support adenosine triphosphate (ATP) levels
Citrate for membrane protection, anticoagulation and pH regulation
Sodium (Sodium Chloride and Sodium Citrate) and dextrose for isotonicity
Dextrose for RBC nutrition

This solution has no pharmacological effect.

14 CLINICAL STUDIES

The in vivo and in vitro quality of RBCs stored for 42 days in ADDITIVE SOLUTION FORMULA 3 (AS-3) storage solution has been assessed in three clinical studies.

In Vivo Recovery of Autologous Radiolabeled RBC

A single-arm, multicenter, in vivo study was conducted to assess the recovery of radiolabeled RBCs 24 hours post infusion. Acceptability of in vivo recovery was determined using established FDA-CBER acceptance criteria. Double collection RBCs (dRBC) were collected using the Trima Accel system and stored in ADDITIVE SOLUTION FORMULA 3 (AS-3) solution for 42 days, then radiolabeled with 51Chromium, and transfused back to the original subject. Table 2 summarizes the in vivo recovery data. Of the 27 units transfused, 26 had > 75% RBC recovery.

Table 2: In vivo Radiolabeled RBC Recovery
Outcome Measure	Study Site (N)	Average (SD)	Min, Max
Abbreviations: Max= Maximum, Min= Minimum, N= Number of Units Transfused, RBC= Red Blood Cell, SD= Standard Deviation
Overall Day 42 infused, 24-hour RBC Radiolabel Recovery (%)	Site 1 (12)	79.3 (5.6)	67.5, 86.5
Overall Day 42 infused, 24-hour RBC Radiolabel Recovery (%)	Site 2 (15)	87.1 (5.5)	79.0, 98.1

FDA-CBER Criteria for Acceptable Recovery: Radiolabeled RBC recoveries should average at least 75%, with a standard deviation of at most 9%. In addition, the 95% one-sided lower confidence limit for the population proportion of successes should be > 70%, with success being defined as an individual red blood cell in vivo recovery of at least 75%. No more than 3 out of 24 data points may have less than 75% radiolabeled red cell recovery at 24 hours post infusion.

The primary outcome was met for RBCs collected on the Trima Accel system and stored in ADDITIVE SOLUTION FORMULA 3 (AS-3) storage solution.

In Vitro RBC Quality Studies

The in vitro quality of RBCs collected in single RBC collection (sRBC) and dRBC procedures using the Trima Accel system was assessed after 42 days of storage in ADDITIVE SOLUTION FORMULA 3 (AS-3) solution in a multicenter, paired study. In vitro quality was determined using established FDA-CBER acceptance criteria. The quality of RBCs stored in ADDITIVE SOLUTION FORMULA 3 (AS-3) solution (test) was compared to RBCs stored in plasma (control). Table summarizes the in vitro RBC quality data for collection on the Trima Accel system and storage in ADDITIVE SOLUTION FORMULA 3 (AS-3) solution.

Table 3: In Vitro Quality Measures for RBCs Collected using the Trima Accel System and Stored in ADDITIVE SOLUTION FORMULA 3 (AS-3)
Outcome Measure	Site (N)	Average (SD)	Min, Max
Abbreviations: HCT = hematocrit, HgB = hemoglobin, Max = Maximum, Min = Minimum, N = Number of Units, RBC = Red Blood Cell, SD = Standard Deviation
* Percent hemolysis was calculated from plasma free hemoglobin using the equation: %Hemolysis = (100 – RBC Product HCT)* Plasma Hgb / (RBC Product Hgb). † The difference in pH between Test and Control on Day 42 was calculated as: ΔpH = │pHTest – pHControl│ ≤ 0.5 where the difference was expected to be less than or equal to 0.5 pH units. ‡ ATP retention was determined for test and control units across all sites and calculated as ATP Level on Day 42 / ATP Level on Day 0. § Normalized potassium was calculated by determining the total number of millimoles of potassium leaked from the RBCs into the supernatant volume and dividing this by the total hemoglobin in the stored product. Normalized Leaked Potassium = Volume(1-Hct/100)(d42[K+] – d0[K+]) / Total Hemoglobin
Day 42 Hemolysis for Single RBC Collection* (%)	Site 1 (32)	0.16 (0.06)	0.06, 0.33
	Site 2 (18)	0.34 (0.18)	0.12, 0.70
	Site 3 (18)	0.26 (0.11)	0.09, 0.47
Day 42 Hemolysis for Double RBC Collection* (%)	Site 1 (25)	0.15 (0.05)	0.06, 0.29
	Site 2 (24)	0.39 (0.19)	0.16, 0.95
	Site 3 (21)	0.26 (0.12)	0.13, 0.61
Change in pH from Day 0 to Day 42 for Single RBC Collection†	Site 1 (31)	0.03 (0.02)	0.00, 0.08
	Site 2 (18)	0.03 (0.03)	0.00, 0.11
	Site 3 (16)	0.02 (0.02)	0.00, 0.07
Change in pH from Day 0 to Day 42 for Double RBC Collection†	Site 1 (23)	0.02 (0.02)	0.00, 0.05
	Site 2 (23)	0.02 (0.03)	0.00, 0.15
	Site 3 (19)	0.02 (0.02)	0.00, 0.08
Ratio of ATP Retention for Single Collection RBC Units (test/control)‡	All sites (65)	1.02 (0.18)	0.46, 1.47
Ratio of ATP Retention for Double Collection RBC Units (test/control)‡	All sites (65)	1.07 (0.19)	0.55, 1.51
Ratio of the Normalized Leaked Potassium for Single Collection RBC Units (test/control)§	All sites (65)	0.98 (0.07)	0.76, 1.13
Ratio of the Normalized Leaked Potassium for Double Collection RBC Units (test/control)§	All Sites (64)	1.00 (0.08)	0.85, 1.24

FDA-CBER Criteria for Acceptable Day 42 Hemolysis: Zero failures (hemolysis ≥ 1% after 42-day storage) out of 60 test units that were not excluded from analysis by the Extreme Studentized Deviate test with α=0.05, which satisfies the binomial distribution testing requirement that, with 95% probability and a one-sided 95% lower confidence limit, the post-storage hemolysis was less than 1% per unit.

There were 0/68 sRBC test units and 0/70 dRBC test units with Day 42 hemolysis ≥ 1%. No donors were excluded as hemolysis was < 1% for all test units. Therefore, the primary objective was met for RBCs stored in ADDITIVE SOLUTION FORMULA 3 (AS-3).

The in vitro quality of sRBC and dRBC units collected using the Trima Accel system was assessed after 42 days of storage in AS-3 solution in a multicenter study. The quality of RBCs was compared between sRBC and dRBC units, and between units A and B of the dRBC collection. Table summarizes the in vitro RBC quality data for collection using the Trima Accel system and storage in ADDITIVE SOLUTION FORMULA 3 (AS-3).

Table 4: In Vitro Quality Measures for RBCs Collected using the Trima Accel System and Stored in ADDITIVE SOLUTION FORMULA 3 (AS-3)
Outcome Measure*	Site	RBC Unit			P Value†
Outcome Measure*	Site	dRBC A	dRBC B	sRBC	dRBC A v dRBC B	sRBC v dRBC
Abbreviations: dRBC A = Unit A of the Double Red Blood Cell Collection, dRBC B = Unit B of the Double Red Blood Cell Collection, sRBC = Single Red Blood Cell Unit, SD = Standard Deviation
* All outcome measures are shown after 42 days of storage in AS-3 solution. † All comparisons were performed using a Student's T-test. A 2-tailed paired comparison was performed for dRBC A v dRBC B. A 2-tailed, two sample, equal variance comparison was performed for sRBC v dRBC units. ‡ Osmotic fragility was measured as percent hemolysis in 0.55% saline at Site 1 and as the percent saline at ≥ 50% hemolysis at Site 2.
Hematocrit (%), mean (SD)	Site 1	54.4 (3.7)	53.9 (3.6)	55.8 (4.4)	0.132	0.253
Hematocrit (%), mean (SD)	Site 2	56.0 (3.9)	53.3 (11.6)	58.4 (3.6)	0.398	0.149
pH, mean (SD)	Site 1	6.4 (0.04)	6.4 (0.05)	6.5 (0.08)	0.760	0.643
pH, mean (SD)	Site 2	6.4 (0.1)	6.4 (0.1)	6.4 (0.1)	0.175	0.217
pCO2, mean (SD)	Site 1	140 (8)	137 (8)	139 (12)	0.172	0.525
pCO2, mean (SD)	Site 2	130.5 (11.7)	130.4 (12.4)	125.6 (11.1)	1.00	0.316
pO2, mean (SD)	Site 1	46 (7)	47 (7)	46 (7)	0.104	0.825
pO2, mean (SD)	Site 2	52.0 (10.6)	51.4 (12.5)	46.2 (3.4)	0.878	0.157
ATP (μmols/g HB), mean (SD)	Site 1	2.6 (0.6)	2.6 (0.6)	2.9 (0.5)	0.759	0.306
ATP (μmols/g HB), mean (SD)	Site 2	3.0 (0.5)	3.0 (0.6)	2.6 (0.5)	0.845	0.110
K (mEq/L), mean (SD)	Site 1	46.5 (7.9)	47.5 (8.2)	49.3 (10.1)	0.396	0.620
K (mEq/L), mean (SD)	Site 2	40.5 (5.8)	41.1 (5.9)	44.7 (5.7)	0.575	0.128
Na (mEq/L), mean (SD)	Site 1	122 (7)	123 (6)	126 (17)	0.016	0.609
Na (mEq/L), mean (SD)	Site 2	105.6 (5.4)	104.2 (5.5)	100.0 (5.5)	0.004	0.069
Total Hemoglobin (g/dL)	Site 1	60.5 (5.8)	60.0 (5.3)	61.0 (4.7)	0.546	0.627
Total Hemoglobin (g/dL)	Site 2	58.5 (5.5)	59.6 (5.8)	60.3 (5.0)	0.264	0.747
Plasma Hemoglobin (mg/dL), mean (SD)	Site 1	149.9 (151.6)	141.2 (145.3)	152.7 (86.3)	0.034	0.815
Plasma Hemoglobin (mg/dL), mean (SD)	Site 2	139.0 (61.0)	126.7 (80.4)	135.5 (82.1)	0.241	0.790
Hemolysis (%), mean (SD)	Site 1	0.33 (0.34)	0.32 (0.34)	0.30 (0.15)	0.05	0.855
Hemolysis (%), mean (SD)	Site 2	0.34 (0.13)	0.31 (0.16)	0.31 (0.19)	0.363	0.995
Osmotic Fragility‡	Site 1	20.0 (14.4)	19.6 (15.2)	31.0 (22.3)	0.885	0.152
Osmotic Fragility‡	Site 2	0.51 (0.03)	0.51 (0.03)	0.49 (0.02)	0.935	0.009

The primary outcome of this study was to demonstrate RBC collection, storage, and viability in vitro.

The sRBC and dRBC units collected were comparable. The hematocrits, blood gasses, ATP, potassium, total hemoglobin, and osmotic fragility were within acceptable ranges following storage. Two statistically significant differences were identified between the A and B units in the dRBC collection at Day 42 (sodium and plasma free hemoglobin), but these differences were not clinically significant. There was no difference between dRBC units in hemolysis following storage in ADDITIVE SOLUTION FORMULA 3 (AS-3). A statistically significant difference was identified in the osmotic fragility of RBCs stored in ADDITIVE SOLUTION FORMULA 3 (AS-3) following sRBC collection or dRBC collection at Day 42, but the difference was not clinically significant. All the RBC units collected averaged less than 1% hemolysis on Day 42. These results are consistent with US and European guidelines for hemolysis on transfusion. ATP recovery was greater than 70% of all units, which is predictive of good in vivo viability, and potassium levels on Day 42 average less than 50 mEq/L indicating good RBC membrane stability over the storage period.

16 HOW SUPPLIED/STORAGE AND HANDLING

ADDITIVE SOLUTION FORMULA 3 (AS-3) is a clear solution supplied in sterile and non-pyrogenic Polyolefin bags.

SIZE	CATALOG NUMBER	NDC NUMBER	QUANTITY PER CASE
100 mL	40832	14537-832-03	36
200 mL	40833	14537-833-03	30
350 mL	40834	14537-834-03	24

STORAGE

Up to 25 °C.

Protect from freezing.

SPL UNCLASSIFIED SECTION

Issued: TBD

Manufactured by

Terumo BCT, Inc.

Lakewood, CO 80215

PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Case Label

Additive Solution Formula 3 (AS-3)

Catalog # 40832 Polyolefin Bag 6 x 6 x 100 mL units

NDC 14537-832-03

Manufactured by TERUMO BCT, INC.

10811 W. Collins Ave.,

Lakewood CO 80215, USA

Made in UK

LPN 1000005747

Use only with Trima Accel red blood cell apheresis collections. See

apheresis device operator's manual for complete instructions. Read the

package insert before use. Sterile. Non-pyrogenic. Sterilized with steam.

Caution: Do not use if the bag is damaged. Use only if solution is clear

and free of particulate matter. Single use bag. Discard any unused

product. Not for direct intravenous infusion. Rx Only.

Recommended storage: Up to 25°C. Protect from freezing.

Each 100 mL contains:

Dextrose Monohydrate USP

1.10 g

Trisodium Citrate Dihydrate USP

0.588 g

Sodium Chloride USP

0.410 g

Monobasic Sodium Phosphate Monohydrate USP

0.276 g

Citric Acid Monohydrate USP

0.042 g

Adenine USP

0.030 g

In Water for Injection USP

Lot

Expiry Date

PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Case Label

PRINCIPAL DISPLAY PANEL - 200 mL Bag Case Label

Additive Solution Formula 3 (AS-3)

Catalog # 40833 Polyolefin Bag 30 x 200 mL units

NDC 14537-833-03

Manufactured by TERUMO BCT, INC.

10811 W. Collins Ave.,

Lakewood CO 80215, USA

Made in UK

LPN 1000005752

Lot

Expiry Date

PRINCIPAL DISPLAY PANEL - 200 mL Bag Case Label

PRINCIPAL DISPLAY PANEL - 350 mL Bag Case Label

Additive Solution Formula 3 (AS-3)

Catalog # 40834 Polyolefin Bag 24 x 350 mL units

NDC 14537-834-03

Manufactured by TERUMO BCT, INC.

10811 W. Collins Ave.,

Lakewood CO 80215, USA

Made in UK

LPN 1000005753

Lot

Expiry Date

PRINCIPAL DISPLAY PANEL - 350 mL Bag Case Label

INGREDIENTS AND APPEARANCE

ADDITIVE FORMULA 3

dextrose monohydrate, trisodium citrate dihydrate, sodium chloride, sodium phosphate, monobasic, monohydrate, citric acid monohydrate, and adenine solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:14537-832
Route of Administration	INTRAVENOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Dextrose Monohydrate (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	Dextrose Monohydrate	1.1 g in 100 mL
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)	ANHYDROUS CITRIC ACID	0.59 g in 100 mL
Sodium Chloride (UNII: 451W47IQ8X) (CHLORIDE ION - UNII:Q32ZN48698)	Sodium Chloride	0.41 g in 100 mL
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR)	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE	0.28 g in 100 mL
Citric Acid Monohydrate (UNII: 2968PHW8QP) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)	ANHYDROUS CITRIC ACID	0.042 g in 100 mL
Adenine (UNII: JAC85A2161) (ADENINE - UNII:JAC85A2161)	Adenine	0.03 g in 100 mL

Ingredient Name	Strength
Inactive Ingredients
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description
Packaging
1	NDC:14537-832-03	6 in 1 CASE
1	NDC:14537-832-01	6 in 1 POUCH
1	NDC:14537-832-00	100 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
NDA	BN001214	05/29/2002

ADDITIVE FORMULA 3

dextrose monohydrate, trisodium citrate dihydrate, sodium chloride, sodium phosphate, monobasic, monohydrate, citric acid monohydrate, and adenine solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:14537-833
Route of Administration	INTRAVENOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Dextrose Monohydrate (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	Dextrose Monohydrate	1.1 g in 100 mL
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)	ANHYDROUS CITRIC ACID	0.59 g in 100 mL
Sodium Chloride (UNII: 451W47IQ8X) (CHLORIDE ION - UNII:Q32ZN48698)	Sodium Chloride	0.41 g in 100 mL
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR)	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE	0.28 g in 100 mL
Citric Acid Monohydrate (UNII: 2968PHW8QP) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)	ANHYDROUS CITRIC ACID	0.042 g in 100 mL
Adenine (UNII: JAC85A2161) (ADENINE - UNII:JAC85A2161)	Adenine	0.03 g in 100 mL

Ingredient Name	Strength
Inactive Ingredients
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description
Packaging
1	NDC:14537-833-03	30 in 1 CASE
1	NDC:14537-833-00	200 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
NDA	BN001214	05/29/2002

ADDITIVE FORMULA 3

dextrose monohydrate, trisodium citrate dihydrate, sodium chloride, sodium phosphate, monobasic, monohydrate, citric acid monohydrate, and adenine solution

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:14537-834
Route of Administration	INTRAVENOUS

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
Dextrose Monohydrate (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	Dextrose Monohydrate	1.1 g in 100 mL
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)	ANHYDROUS CITRIC ACID	0.59 g in 100 mL
Sodium Chloride (UNII: 451W47IQ8X) (CHLORIDE ION - UNII:Q32ZN48698)	Sodium Chloride	0.41 g in 100 mL
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR)	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE	0.28 g in 100 mL
Citric Acid Monohydrate (UNII: 2968PHW8QP) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL)	ANHYDROUS CITRIC ACID	0.042 g in 100 mL
Adenine (UNII: JAC85A2161) (ADENINE - UNII:JAC85A2161)	Adenine	0.03 g in 100 mL

Ingredient Name	Strength
Inactive Ingredients
Water (UNII: 059QF0KO0R)

#	Item Code	Package Description
Packaging
1	NDC:14537-834-03	24 in 1 CASE
1	NDC:14537-834-00	350 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Marketing Information
NDA	BN001214	05/29/2002

Labeler - Terumo BCT, Ltd (233649834)

Registrant - Terumo BCT, Inc. (801679200)

Name	Address	ID/FEI	Business Operations
Establishment
Terumo BCT, Ltd		233649834	LABEL(14537-832, 14537-833, 14537-834) , ANALYSIS(14537-832, 14537-833, 14537-834) , STERILIZE(14537-832, 14537-833, 14537-834) , MANUFACTURE(14537-832, 14537-833, 14537-834)

Revised: 12/2021

Document Id: a7c8359b-69ef-497d-85f9-205ffdec83cb

Set id: 9a5247a1-cc05-442d-b2d0-950f887f03c2

Version: 1

Effective Time: 20211215

Search by Drug Name or NDC

NDC 14537-0834-03 Additive Formula 3 .03; .042; 1.1; .41; .28; .59 g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL Details

Additive Formula 3 .03; .042; 1.1; .41; .28; .59 g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL

Product Information

Package

Package Images

NDC 14537-0834-03 (14537083403)

Contents

Standard Product Labeling (SPL)/Prescribing Information SPL 9a5247a1-cc05-442d-b2d0-950f887f03c2 Details

HIGHLIGHTS OF PRESCRIBING INFORMATION

INDICATIONS AND USAGE

DOSAGE AND ADMINISTRATION

DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Table Of Contents

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information

2.2 Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

6 ADVERSE REACTIONS

8 USE IN SPECIFIC POPULATIONS

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

SPL UNCLASSIFIED SECTION

PRINCIPAL DISPLAY PANEL - 100 mL Bag Pouch Case Label

PRINCIPAL DISPLAY PANEL - 200 mL Bag Case Label

PRINCIPAL DISPLAY PANEL - 350 mL Bag Case Label

INGREDIENTS AND APPEARANCE